Sentiment-Signal
Score-Verlauf (90 Tage)
Kritische 8-K Meldungen
| Datum | Meldung | Schwere | Filing | Auszug |
|---|---|---|---|---|
| 05.12.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer |
| 21.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers |
| 08.08.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | orth by specific reference in such filing. Item 5.02. – Departure of Directors or Certain Officers; Election of Direct |
| 13.07.2023 | Item 5.02 — Abgang Schlüsselpersonen | HOCH | SEC | Item 5.02. – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Offic |
Stammdaten
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Unternehmen & Branche
| Name | AMICUS THERAPEUTICS, INC. |
|---|---|
| Ticker | FOLD |
| CIK | 0001178879 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 4,55 Mrd. USD |
| Beta | 0,48 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 634,210,000 | -27,110,000 | -0.09 | 949,870,000 | 274,241,000 |
| 2025-09-30 | 10-Q | 169,061,000 | 17,306,000 | 0.06 | 868,811,000 | 230,424,000 |
| 2025-06-30 | 10-Q | 154,688,000 | -24,420,000 | -0.08 | 815,303,000 | 204,304,000 |
| 2025-03-31 | 10-Q | 125,249,000 | -21,686,000 | -0.07 | 789,839,000 | 193,558,000 |
| 2024-12-31 | 10-K | 528,295,000 | -56,106,000 | -0.18 | 785,033,000 | 194,045,000 |
| 2024-09-30 | 10-Q | 141,517,000 | -6,729,000 | -0.02 | 786,557,000 | 178,825,000 |
| 2024-06-30 | 10-Q | 126,669,000 | -15,697,000 | -0.05 | 749,484,000 | 132,523,000 |
| 2024-03-31 | 10-Q | 110,403,000 | -48,419,000 | -0.16 | 721,789,000 | 130,694,000 |
| 2023-12-31 | 10-K | 399,356,000 | -151,584,000 | -0.51 | 777,880,000 | 160,174,000 |
| 2023-09-30 | 10-Q | 103,501,000 | -21,577,000 | -0.07 | 764,084,000 | 133,237,000 |
| 2023-06-30 | 10-Q | 94,503,000 | -43,232,000 | -0.15 | 730,093,000 | 111,581,000 |
| 2023-03-31 | 10-Q | 86,270,000 | -52,932,000 | -0.18 | 700,519,000 | 102,573,000 |
| 2022-12-31 | 10-K | 329,233,000 | -236,568,000 | -0.82 | 724,167,000 | 123,047,000 |
| 2022-09-30 | 10-Q | 81,691,000 | -33,286,000 | -0.12 | 759,528,000 | 132,565,000 |
| 2022-06-30 | 10-Q | 80,731,000 | -62,157,000 | -0.21 | 800,589,000 | 173,425,000 |
| 2022-03-31 | 10-Q | 78,715,000 | -85,260,000 | -0.30 | 826,938,000 | 238,617,000 |
| 2021-12-31 | 10-K | 305,514,000 | -250,460,000 | -0.92 | 905,140,000 | 307,369,000 |
| 2021-09-30 | 10-Q | 79,545,000 | -50,294,000 | -0.19 | 956,675,000 | 376,629,000 |
| 2021-06-30 | 10-Q | 77,413,000 | -51,225,000 | -0.19 | 786,892,000 | 213,910,000 |
| 2021-03-31 | 10-Q | 66,402,000 | -65,664,000 | 810,034,000 | 250,896,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-02 | Campbell Bradley L | Director, Officer, President and CEO | Open Market Sale | -22,500 | 14.35 | -322,839.00 | -77,5% | |
| 2026-01-20 | Campbell Bradley L | Director, Officer, President and CEO | Open Market Sale | -75,000 | 14.31 | -1,073,182.50 | -257,6% | |
| 2025-12-19 | Clark David Michael | Officer, Chief People Officer | Open Market Sale | -25,642 | 14.17 | -363,380.47 | -87,2% | |
| 2025-12-15 | Clark David Michael | Officer, Chief People Officer | Open Market Sale | -25,643 | 11.00 | -282,073.00 | -67,7% | |
| 2025-12-15 | Campbell Bradley L | Director, Officer, President and CEO | Open Market Sale | -77,926 | 10.86 | -846,011.41 | -203,1% | |
| 2025-12-01 | Campbell Bradley L | Director, Officer, President and CEO | Open Market Sale | -14,587 | 10.01 | -146,011.49 | -35,1% | |
| 2025-11-26 | Rosenberg Ellen | Officer, Chief Legal Officer | Open Market Sale | -23,621 | 10.00 | -236,210.00 | -56,7% | |
| 2025-11-25 | Rosenberg Ellen | Officer, Chief Legal Officer | Open Market Sale | -36,000 | 10.00 | -360,000.00 | -86,4% | |
| 2025-11-24 | Clark David Michael | Officer, Chief People Officer | Open Market Sale | -25,643 | 10.10 | -258,932.76 | -62,2% | |
| 2025-11-24 | Campbell Bradley L | Director, Officer, President and CEO | Open Market Sale | -14,587 | 10.04 | -146,522.04 | -35,2% | |
| 2025-11-24 | Rosenberg Ellen | Officer, Chief Legal Officer | Open Market Sale | -36,000 | 10.06 | -362,268.00 | -87,0% | |
| 2025-11-24 | Castelli Jeff | Officer, Chief Development Officer | Open Market Sale | -76,158 | 10.16 | -773,658.66 | -185,7% | |
| 2025-11-04 | Clark David Michael | Officer, Chief People Officer | Open Market Sale | -25,643 | 9.51 | -243,859.80 | -58,5% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.